Viridian Therapeutics
VRDN
29.96
-1.48
-4.71%
Viridian Therapeutics
US · VRDN
#2731 by market cap
Listed 1970
29.96
-1.48
-4.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 117.26% -0.14pp
- Institutions
- 278 +5
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund69.20%
Hedge Fund32.95%
VC/PE Fund8.75%
Public Company2.97%
Private Company1.46%
Sovereign Wealth Fund1.32%
Government Pension Fund0.30%
Insurance Company0.28%
Top holders as of 2026-09-30
FMR
15.42% · 17.51M sh
BlackRock
8.22% · 9.33M sh
Bellevue Asset Management AG
5.93% · 6.73M sh
Paradigm Biocapital Advisors LP
5.92% · 6.72M sh
T. Rowe Price Group, Inc.
5.06% · 5.75M sh
Point72 Asset Management, L.P.
5.01% · 5.69M sh
Fairmount Funds Management LLC
4.48% · 5.09M sh
State Street Global Advisors
4.29% · 4.88M sh
Vanguard Capital Management, LLC
4.19% · 4.75M sh
Deep Track Capital, LP
3.16% · 3.59M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Radhika Tripuraneni | Chief Medical Officer | 0.04% |
| Stephen Mahoney | Chief Executive Officer | 0.03% |
| Thomas Beetham | Chief Operating Officer | 0.01% |
| Seth Harmon | Chief Financial Officer | 0.01% |
| Arlene Morris | Independent Director | -- |
| Jeffrey Ajer | Independent Director | -- |
| Tomas Kiselak | Independent Chairperson of Board | -- |
| Christopher Cain | Independent Director | -- |
| Jennifer Moses | Independent Director | -- |
| Fairmount Funds Management LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Jennifer Tousignant | Chief Legal Officer | Open Market Disposition | -4,212 | $24.50 |
| 2026-08-18 | Jennifer Tousignant | Chief Legal Officer | Derivative Exercise and Sale | -10,000 | $14.41–24.50 |
| 2026-08-13 | Radhika Tripuraneni | Chief Medical Officer | Derivative Exercise and Retained | +40,000 | $13.21 |
| 2026-06-30 | Arlene Morris | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Jeffrey Ajer | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Tomas Kiselak | Independent Chairperson of Board | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Christopher Cain | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Jennifer Moses | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Sarah Gheuens | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-05-10 | Fairmount Funds Management LLC | -- | Open Market Acquisition | +1,176,470 | $17.00 |
| 2026-03-03 | Thomas Beetham | Chief Operating Officer | Intent to Sell (Form 144) | -3,048 | $30.19 |
| 2026-03-03 | Stephen Mahoney | Chief Executive Officer | Intent to Sell (Form 144) | -7,408 | $30.19 |
| 2026-03-03 | Seth Harmon | Chief Financial Officer | Intent to Sell (Form 144) | -2,031 | $30.19 |
| 2026-03-03 | Jennifer Tousignant | Chief Legal Officer | Intent to Sell (Form 144) | -1,675 | $30.19 |
| 2026-03-02 | Thomas Beetham | Chief Operating Officer | Sale to Issuer | -3,048 | $30.19 |
| 2026-03-02 | Thomas Beetham | Chief Operating Officer | Derivative Exercise and Retained | +9,409 | -- |
| 2026-03-02 | Stephen Mahoney | Chief Executive Officer | Sale to Issuer | -7,408 | $30.19 |
| 2026-03-02 | Stephen Mahoney | Chief Executive Officer | Derivative Exercise and Retained | +18,357 | -- |
| 2026-03-02 | Seth Harmon | Chief Financial Officer | Sale to Issuer | -2,031 | $30.19 |
| 2026-03-02 | Seth Harmon | Chief Financial Officer | Derivative Exercise and Retained | +6,267 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Viridian Therapeutics discussion 0 comments